JP5694928B2 - ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 - Google Patents

ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 Download PDF

Info

Publication number
JP5694928B2
JP5694928B2 JP2011517819A JP2011517819A JP5694928B2 JP 5694928 B2 JP5694928 B2 JP 5694928B2 JP 2011517819 A JP2011517819 A JP 2011517819A JP 2011517819 A JP2011517819 A JP 2011517819A JP 5694928 B2 JP5694928 B2 JP 5694928B2
Authority
JP
Japan
Prior art keywords
cells
heme
hemoglobin
blood
oxidative stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011517819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505154A5 (enExample
JP2012505154A (ja
Inventor
アケルストロム，ボー
ハンソン，ステファン
オルソン，マーティン，レナース
オルソン，マグナス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guard Therapeutics International AB
Original Assignee
A1M Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma AB filed Critical A1M Pharma AB
Publication of JP2012505154A publication Critical patent/JP2012505154A/ja
Publication of JP2012505154A5 publication Critical patent/JP2012505154A5/ja
Application granted granted Critical
Publication of JP5694928B2 publication Critical patent/JP5694928B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
JP2011517819A 2008-07-18 2009-07-17 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用 Expired - Fee Related JP5694928B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US13533808P 2008-07-18 2008-07-18
US61/135,338 2008-07-18
DKPA200801024 2008-07-18
DKPA200801024 2008-07-18
US18938108P 2008-08-18 2008-08-18
DKPA200801116 2008-08-18
US61/189,381 2008-08-18
DKPA200801116 2008-08-18
US19750608P 2008-10-27 2008-10-27
DKPA200801478 2008-10-27
US61/197,506 2008-10-27
DKPA200801478 2008-10-27
PCT/EP2009/005217 WO2010006809A2 (en) 2008-07-18 2009-07-17 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014236500A Division JP6406987B2 (ja) 2008-07-18 2014-11-21 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用

Publications (3)

Publication Number Publication Date
JP2012505154A JP2012505154A (ja) 2012-03-01
JP2012505154A5 JP2012505154A5 (enExample) 2012-09-06
JP5694928B2 true JP5694928B2 (ja) 2015-04-01

Family

ID=41550762

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011517819A Expired - Fee Related JP5694928B2 (ja) 2008-07-18 2009-07-17 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2014236500A Expired - Fee Related JP6406987B2 (ja) 2008-07-18 2014-11-21 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2015241096A Expired - Fee Related JP6175478B2 (ja) 2008-07-18 2015-12-10 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014236500A Expired - Fee Related JP6406987B2 (ja) 2008-07-18 2014-11-21 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
JP2015241096A Expired - Fee Related JP6175478B2 (ja) 2008-07-18 2015-12-10 ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用

Country Status (12)

Country Link
US (1) US10350268B2 (enExample)
EP (2) EP2313106B1 (enExample)
JP (3) JP5694928B2 (enExample)
AU (1) AU2009270435B2 (enExample)
CA (1) CA2730531A1 (enExample)
DK (2) DK2313106T3 (enExample)
ES (2) ES2614490T3 (enExample)
HR (2) HRP20160760T1 (enExample)
HU (2) HUE030274T2 (enExample)
PL (2) PL2313106T3 (enExample)
PT (1) PT2638915T (enExample)
WO (1) WO2010006809A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
NZ578077A (en) 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
PL2900254T3 (pl) * 2012-09-05 2017-02-28 A1M Pharma Ab Alfa-1 mikroglobulina do użycia w leczeniu chorób związanych z mitochondriami
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3102224B1 (en) 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
SG11201807352XA (en) * 2016-03-18 2018-09-27 A1M Pharma Ab Novel alpha-1-microglobulin derived proteins and their use
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
WO2018094023A2 (en) * 2016-11-16 2018-05-24 Anand Prasad Cyclic dipeptides and wound healing
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
EP3703729A1 (en) * 2017-11-03 2020-09-09 Guard Therapeutics International AB Use of alpha-1-microglobulin for protection of bone marrow cells
JP6906807B2 (ja) * 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置
AU2024219294A1 (en) 2023-02-08 2025-07-10 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) * 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE10125883A1 (de) 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AR045074A1 (es) * 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20070292421A1 (en) 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
NZ578077A (en) 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin

Also Published As

Publication number Publication date
WO2010006809A2 (en) 2010-01-21
AU2009270435B2 (en) 2014-10-16
PT2638915T (pt) 2017-01-10
EP2638915B1 (en) 2016-10-19
JP2016102125A (ja) 2016-06-02
AU2009270435A1 (en) 2010-01-21
HRP20160760T1 (hr) 2016-08-12
HUE027953T2 (en) 2017-01-30
DK2638915T3 (en) 2017-01-30
EP2638915A1 (en) 2013-09-18
JP2015071620A (ja) 2015-04-16
PL2313106T3 (pl) 2016-08-31
US10350268B2 (en) 2019-07-16
HUE030274T2 (en) 2017-05-29
WO2010006809A3 (en) 2010-05-27
JP6175478B2 (ja) 2017-08-02
DK2313106T3 (en) 2016-07-25
JP6406987B2 (ja) 2018-10-17
HRP20161808T1 (hr) 2017-02-24
ES2571956T3 (es) 2016-05-27
US20110190208A1 (en) 2011-08-04
PL2638915T3 (pl) 2017-04-28
CA2730531A1 (en) 2010-01-21
ES2614490T3 (es) 2017-05-31
JP2012505154A (ja) 2012-03-01
EP2313106B1 (en) 2016-03-30
EP2313106A2 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
JP6175478B2 (ja) ラジカルスカベンジャー及び抗酸化剤アルファ−１−ミクログロブリンの医薬的使用
Yao et al. MG53 permeates through blood-brain barrier to protect ischemic brain injury
Ashafaq et al. S-allyl cysteine mitigates oxidative damage and improves neurologic deficit in a rat model of focal cerebral ischemia
US9006180B2 (en) Methods for treating tourniquet-induced injuries
Hu et al. Deferoxamine therapy reduces brain hemin accumulation after intracerebral hemorrhage in piglets
JP2011503012A (ja) 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン
Zhang et al. Metformin attenuates early brain injury after subarachnoid hemorrhage in rats via AMPK-dependent mitophagy
JP2018203756A (ja) ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン
Yang et al. SS31 ameliorates oxidative stress via the restoration of autophagic flux to protect aged mice from hind limb ischemia
Ye et al. Gas6/Axl signaling promotes hematoma resolution and motivates protective microglial responses after intracerebral hemorrhage in mice
Harkin et al. Reperfusion injury is greater with delayed restoration of venous outflow in concurrent arterial and venous limb injury
CN110934131A (zh) 一种提高缺血再灌注后器官或复合组织移植物保存质量的方法
AU2014262273B2 (en) Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
EP1057489A1 (en) Preventives or remedies for ischemic diseases
CN105233256A (zh) 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
RU2747121C1 (ru) Способ применения средства на основе модифицированного пероксиредоксина 2 человека для коррекции последствий ишемически-реперфузионного поражения почек
RU2405558C2 (ru) Лекарственный препарат для лечения гипоксических и токсических митохондриальных нарушений и способ его получения
Sohn et al. Protective effects of natrii sulfas on cerebral focal ischemia induced by MCAO in rats
Minaei et al. Protective effect of nano magnesium oxide on renal ischemia/reperfusion injury in male Wistar rats
WO2017048157A1 (ru) Комбинаторная терапия для лечения геморрагического шока и последствий черепно-мозговой травмы
JP2021501750A (ja) 骨髄細胞の保護のためのアルファ−１−ミクログロブリンの使用
Harkin et al. Vascular Surgical Society of Great Britain and Ireland

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120717

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150205

R150 Certificate of patent or registration of utility model

Ref document number: 5694928

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees